Changing the way we deliver immune-based cancer drugs could reduce costs by 14%
ANN ARBOR, Michigan — A new analysis finds that up to millions of dollars could be saved annually on cancer immunotherapy treatments across the Veterans Health Administration by reconsidering how those drugs are delivered.
It’s a concept that could be applied to all cancer centers nationwide. Immune checkpoint inhibitors were initially tested and approved at weight-based dosages but then moved to one-size-fits-all flat doses, in part to reduce drug waste. But researchers from the University of Michigan Rogel Cancer Center found that if vials intended for a single ...













